Uterine Cancer Market Assessment, By Types [Endometroid Adenocarcinoma, Serous Adenocarcinoma, Papillary Serous Carcinoma, Uterine Sarcoma, Others], By Modality [Diagnosis, Treatment], By End-users [Hospitals, Ambulatory Surgical Centers, Specialty Clinic

Uterine Cancer Market Assessment, By Types [Endometroid Adenocarcinoma, Serous Adenocarcinoma, Papillary Serous Carcinoma, Uterine Sarcoma, Others], By Modality [Diagnosis, Treatment], By End-users [Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Pharmacies, Others], By Region, Opportunities and Forecast, 2017-2031F

Global uterine cancer market size was valued at USD 26.05 billion in 2023, expected to reach USD 38.63 billion in 2031, with a CAGR of 5.05% for the forecast period between 2024 and 2031. The global uterine cancer market is subject to a multitude of factors that are driving the market. The contributing factors consist of rising prevalence of uterine cancer, advancements in screening and diagnostic technologies, increased focus on research, novel treatment approaches, focused initiatives on awareness and education, impact of aging population, and government-led programs and policies.

The increasing incidence of uterine cancer stands as a prominent driver for the growth of global uterine cancer market. The trend is largely attributed to factors like obesity, lifestyle changes, and rising aging population. As the number of diagnosed patients continues to rise, there is a growing demand for effective screening, diagnostic, and treatment options. Advancements in screening and diagnostic technologies play a pivotal role in early detection, aiding in better patient outcomes. Modalities such as ultrasound, MRI, and minimally invasive techniques have revolutionized the way uterine cancer is diagnosed and treated, enabling healthcare professionals to detect the disease at early stages. Novel approaches such as targeted therapies, immunotherapies, and precision medicine are gaining popularity.

Growing geriatric is contributing to the increased risk of uterine cancer, as postmenopausal women are particularly vulnerable. Government initiatives and policies are integral in shaping the global uterine cancer market. These include funding for research, access to healthcare services, and the development of comprehensive cancer care programs. Clinical trials and ongoing scientific research are essential for uncovering innovative treatment options and therapies. Patient advocacy groups exert influence, raising awareness, providing support, and advocating for enhanced care and treatment access. Their efforts contribute to an environment where patients receive comprehensive care and support beyond medical treatment.

Rising Prevalence of Uterine Cancer

The increasing prevalence of uterine cancer plays a pivotal role in driving the global uterine cancer market. According to BMC Women’s Health, as of 2020, there were an estimated 417,000 new uterine cancer diagnoses worldwide, revealing a troubling upward pattern. In 2022, more than 65,000 endometrial cancer patients were diagnosed in the United States. Notably, the incidence of uterine cancer has doubled among women under the age of 40, underscoring the essential need for more efficient screening and treatment options for the younger demographic. In the United States, uterine cancer is anticipated to rank as the fourth most common cancer among new cases and the sixth leading cause of female cancer-related deaths in 2023. It highlights the urgent demand for ongoing research, improved diagnostic tools, and the advancement of pioneering therapies to address the rise in uterine cancer incidence and mortality rates. Vigorous efforts in early detection, awareness campaigns, and the evolution of treatment modalities are crucial components in effectively addressing this public health challenge.

Growing Focus on Research

The growth of the global uterine cancer market is significantly propelled by increasing investments in research and development efforts focused on innovative treatments. These investments drive the discovery and development of novel therapies, which can improve patient outcomes and quality of life. Research initiatives contribute to expanding treatment options, including targeted therapies and immunotherapies, offering new hope for uterine cancer patients. Furthermore, as research uncovers more effective treatments, it encourages pharmaceutical and biotechnology companies to invest in the development of these therapies, fostering market growth and ultimately enhancing the prognosis for those affected by uterine cancer.

In October 2023, Dr. Tae Hoon Kim, PhD, who serves as an assistant professor at the University of Missouri School of Medicine, received a substantial grant. The five-year grant, totaling USD 2.26 million, was awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the National Institutes of Health. Dr. Kim's research project focuses on investigating treatments aimed at preserving fertility in women of reproductive age who are affected by endometrial hyperplasia.

Government Initiatives

Governments globally are implementing initiatives to raise awareness about uterine cancer, recognizing its significance in public health. By promoting education and regular screenings, these campaigns aim to reduce the stigma associated with uterine cancer and encourage early detection. As awareness grows, more women are likely to seek timely medical attention, driving the demand for diagnostic and treatment services. It in turn, contributes to the expansion of global uterine cancer market, as healthcare providers and pharmaceutical companies respond to the increased demand, ultimately improving outcomes for patients through early intervention and effective treatments. In June 2023, Israel and other countries attended Endometrial Cancer Awareness Week to combat the lack of awareness among women and the insufficient funding allocated for the diagnosis and treatment of the condition.

Immunotherapy is Expected to Witness Significant Growth Over the Forecasted Period

The global uterine cancer market is witnessing a substantial uptick in the utilization of immunotherapy as a preferred treatment modality. Immunotherapy, a therapeutic approach that leverages the body's immune system to target and eliminate cancer cells, has displayed encouraging outcomes in the context of uterine cancer treatment. The growing demand for immunotherapy is primarily rooted in its potential to offer more effective and less invasive treatment alternatives, especially for cases at advanced or recurrent stages. Consequently, both pharmaceutical companies and research institutions are investing in the development of tailored immunotherapeutic agents for uterine cancer. The growing interest in immunotherapy stands as an important catalyst in the expansion of the global uterine cancer market.

In May 2023, the addition of Imfinzi plus Lynparza and Imfinzi alone resulted in notable enhancements in progression-free survival for individuals with advanced endometrial cancer when incorporated with chemotherapy. DUO-E marks the inaugural global Phase III trial where the combination of immunotherapy and PARP inhibition showcased substantial clinical advantages within this context.

Development of Novel Treatment Methods for High-Risk Uterine Cancer

High-risk uterine cancer typically presents with factors like advanced stage, aggressive histology, or recurring tumors, making it a formidable challenge for patients and healthcare providers. The increasing incidence of high-risk uterine cancer underscores the critical need for effective therapeutic interventions, including advanced surgical techniques, radiation therapy, targeted therapies, and immunotherapies. As these treatment options evolve and become more accessible, the growing demand to address high-risk uterine cancer becomes a driving force in the global healthcare market.

As an example, in February 2023, GSK plc disclosed that the US Food and Drug Administration (FDA) had issued complete approval for Jemperli (dostarlimab-gxly). The approval pertains to the treatment of adult patients dealing with recurrent or advanced endometrial cancer, specifically those characterized by a mismatch repair-deficiency (dMMR) as determined through an FDA-sanctioned test. These patients must have experienced disease progression after prior treatment with a platinum-based regimen in any therapeutic context who are not considered suitable candidates for curative surgical procedures or radiation therapy.

Future Market Scenario

The future of the global uterine cancer market looks promising, contributing to its overall growth. Several factors are driving growth in the market. Ongoing advancements in medical research and technology are continually expanding our understanding of uterine cancer, leading to the development of more targeted and effective treatment options. Increasing awareness and early detection efforts will likely reduce late-stage diagnoses, improving treatment outcomes. Additionally, the rising incidence of uterine cancer, driven by factors such as an aging population and lifestyle changes, creates a sustained demand for healthcare services. Furthermore, the emergence of innovative therapies, including immunotherapies and precision medicine, offers new avenues for treatment, giving hope to patients with limited options. The factors collectively ensure a promising trajectory for the global uterine cancer market, where research, innovation, and awareness campaigns converge to enhance patient care and drive market growth.

Key Players Landscape and Outlook

The global uterine cancer market is witnessing significant growth due to strategic collaborations among major pharmaceutical companies. These partnerships bring expertise, resources, and research capabilities together from multiple organizations to accelerate the development of innovative therapies and treatment approaches. The collaborations facilitate the combination of knowledge and technologies, resulting in faster drug discovery and development. They enable a more efficient response to the complex challenges posed by uterine cancer, ultimately benefiting patients by expanding treatment options and improving outcomes. The synergy among pharmaceutical companies spurs innovation and drives market expansion, meeting the growing demand for effective uterine cancer treatments.

In June 2022, Astellas and Sutro Biopharma revealed a global strategic partnership aimed at advancing innovative immunostimulatory antibody-drug conjugates (iADCs) for the treatment of uterine cancer. iADCs represents a cutting-edge therapeutic approach in uterine cancer treatment.